Latest Hotspot

Neurogene to Present Early Results on NGN-401 Gene Therapy for Rett Syndrome at ASGCT Conference

25 April 2024
3 min read

Neurogene Inc. a clinical-stage enterprise dedicated to developing transformative genetic treatments for individuals and families grappling with rare neurological disorders, disclosed that preliminary data on safety and tolerability from its active Phase 1/2 gene therapy trial targeting Rett syndrome is set to be showcased at the upcoming Annual Meeting of the American Society for Gene and Cell Therapy.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately. 图形用户界面, 文本, 应用程序, Teams

描述已自动生成

The results indicate that the NGN-401 gene therapy candidate has generally been tolerated well, with no serious adverse events linked to the treatment or procedure, nor indications of toxicity due to overexpression of MeCP2 reported in any of the patients, including one with a mild variant likely to retain some MeCP2 function.

Rachel McMinn, Ph.D., Founder and CEO of Neurogene, commented, We are eager to present the preliminary but positive safety profile of NGN-401, employing our unique EXACT transgene regulation technology to administer a full-length MECP2 gene specifically to critical brain regions implicated in Rett syndromes pathophysiology. She added, Rett syndrome presents as a complex neurological disorder with limited treatment leeway. Traditional gene therapy models have struggled to adjust protein levels therapeutically without causing harmful overexpression. Thus, we find it crucial to discuss these safety results at the ASGCT Meeting before our projected interim efficacy results in the fourth quarter of 2024. We now have several months of data from three patients indicating that NGN-401 has been largely well-received.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 表格

描述已自动生成

According to the data provided by the Synapse Database, As of April 24, 2024, there are 12 investigational drugs for the MECP2 target, including 5 indications, 15 R&D institutions involved, with related clinical trials reaching 4, and as many as 2310 patents.

NGN-401 shows promise as a potential treatment for Rett Syndrome, a rare congenital disorder affecting the nervous system. Its AAV-based gene therapy approach and targeting of MECP2 indicate a novel and targeted therapeutic strategy. The drug is currently in Phase 1/2 of clinical development, and its regulatory designations as a Rare Pediatric Disease, Fast Track, and Orphan Drug highlight its potential to address unmet medical needs and provide significant benefits to patients. Further research and clinical trials will be necessary to determine the safety and efficacy of NGN-401, but it represents a potential breakthrough in the treatment of Rett S.

图形用户界面, 文本, 应用程序

描述已自动生成

Adicet Bio Showcases Preclinical Readiness of ADI-270 for IND at 27th ASGCT Meeting
Latest Hotspot
3 min read
Adicet Bio Showcases Preclinical Readiness of ADI-270 for IND at 27th ASGCT Meeting
25 April 2024
Adicet Bio presents preclinical findings indicating IND preparedness for ADI-270 during a talk at the 27th Annual ASGCT Meeting.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 25
Pharma Frontiers
11 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 25
25 April 2024
April 25th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
ASLAN Pharmaceuticals Announces Positive Early Results from Phase 2 Eblasakimab Trial in Atopic Dermatitis Patients Previously on Dupilumab
Latest Hotspot
3 min read
ASLAN Pharmaceuticals Announces Positive Early Results from Phase 2 Eblasakimab Trial in Atopic Dermatitis Patients Previously on Dupilumab
24 April 2024
ASLAN Pharmaceuticals Reports Encouraging Preliminary Outcomes from a Phase 2 Trial of Eblasakimab in Patients with Atopic Dermatitis Previously Treated with Dupilumab.
Read →
Compilation of 13 FDA-Approved ADC (Antibody-Drug Conjugate) Medications
Graphic Pharma
19 min read
Compilation of 13 FDA-Approved ADC (Antibody-Drug Conjugate) Medications
24 April 2024
At present, 13 types of ADCs have been approved by the United States Food and Drug Administration (FDA), with over 200 additional ADCs at various stages of clinical trials.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.